Halogenated Hydrocarbon Active Ingredients TRIZ Cases

Combining nonsteroidal glucocorticoid receptor modulators with chemotherapy reduces pancreatic tumor load while limiting toxicity.

Immiscible perfluorocarbon liquid isolates blood and applies pressure in middle ear surgery, improving visualization and suction-based removal.

A perfluorooctyl bromide emulsion carries oxygen and targeted NIR agents to tumors, improving retention, visualization, and PDT killing.

Oil-bound dried red seaweed improves mixing, palatability, and compound stability while reducing methane emissions in ruminants.

A bromoform feed composition uses MCT and milk-derived stabilizers to curb ruminant methane while improving formulation stability and intake.

Filtering the microbubble-containing solvent before electrolyte addition suppresses bubble loss and enables high-density electrolyte solutions.

Semifluorinated alkane eye drops enrich ocular tissue for delayed release, sustaining tear film lubrication without visual disturbance.

A non-aqueous semifluorinated alkane vehicle keeps tetracycline injections stable and ready to use without reconstitution.

Mitochondrial profiling identifies hyper-metabolic e-CSCs, enabling selective inhibition to curb tumor recurrence and metastasis.

Haloalkanes with medium-chain triglycerides shift rumen fermentation to cut methane emissions while maintaining feed stability and animal intake.

A direct-compression cariprazine tablet balances fast oral disintegration, taste masking, strength, and bioavailability to improve patient compliance.

Reduced oxygen carriers remove carbon monoxide from hemoglobin without hyperbaric chambers, enabling faster treatment of carboxyhemoglobinemia.

Amino acid bearing carbonates improve pterostilbene water solubility and stability for potential NAFLD and NASH treatment.

Specific deuterium substitution slows metabolism in etifoxine analogs, extending drug action and helping stabilize therapeutic levels.

Perfluorinated alkane eye drops address ocular surface damage and dryness without preservatives, supporting tear-film stability in dry eye disease.

Nitrogen-substituted chalcone derivatives target tubulin to inhibit TNBC cell growth, induce apoptosis, and reduce metastasis.

A biodegradable PLA/PBS bolus uses wax-based encapsulation to control hydrophobic methane inhibitor release and reduce methane production in ruminants.

Phenyl carbamate compounds address drug-resistant epilepsy by suppressing seizures with lower toxicity than established antiepileptic drugs.

Unsymmetrical meso-substituents and directed porphyrin-to-chlorin conversion improve red and near-infrared absorption while limiting isomer separation.

PLA and PBAT bolus housings address stomach stability while sustaining methane-inhibitor release in ruminant animals.

Perfluorocarbon carries oxygen and photosensitizer to improve gas retention during PDT.

Perfluorocarbon compositions target and retain gas therapies at tumors while supporting PDT and fluorescence-guided tissue visualization.

Fluorescence screening identifies compounds that shift macrophages toward M1-like or M2-like states for targeted disease treatment.

Methane inhibitors help ruminants manage stress by increasing rumen methylsulfonylmethane.

This case combines chemotherapy with selective GR modulation to target pancreatic tumors while reducing harm to healthy tissues.

Microfluidic preparation of fluorocarbon nanodroplets uses biocompatible surfactants to ensure uniform size distribution.

Gallium silicate glass releases therapeutic ions to form a stable hydrogel matrix, preventing aneurysm recanalization.

Halogenated stilbene analogs inhibit methionine adenosyltransferase 2A to block cancer cell proliferation.

Low-temperature complexation with sulfobutylether-β-cyclodextrin stabilizes volatile flurane for aqueous administration.

Merging M4N with metabolic modulators overcomes host toxicity limits while achieving complete tumor eradication.

Replacing high-temperature phosphate materials with metal carboxylates prevents thermal degradation of vitamins and bromoform during bolus formation.

Pyrazole derivatives inhibit NMDA NR2B receptors to address hyperactivity without affecting other subunits.

Small molecule inhibitors replace complex antibody therapies to enable oral administration and simplify manufacturing while maintaining therapeutic efficacy.

Cyclodextrin encapsulation protects 3-halopyruvates from nucleophilic attack and aqueous degradation, enabling effective systemic administration.

Optimized branched semifluorinated alkanes treat dry eye disease by stabilizing the tear film while maintaining low viscosity for easy topical administration.

PPARδ agonists shift LDL particles from small, dense forms to larger structures, reducing atherogenic risk factors like Apolipoprotein B-100.

Formula I amino-pyrrolopyrimidinone compounds inhibit Bruton's tyrosine kinase to resolve efficacy and safety trade-offs in treating immune disorders.

Administering test agents during a 1-7 day window after androgen deprivation induces vascular endothelial cell apoptosis in human prostate xenografts.

Novel 3-hydroxypyrimidine-2,4-dione-5-carboxamide compounds inhibit HIV integrase strand transfer with nanomolar potency.

Administers a three-drug combination of volatile anesthetics and anti-convulsants to arrest status epilepticus before it becomes refractory.

Administering LAP inhibitors suppresses tumors by increasing IFNγ and TNFα expression to overcome cancer cell heterogeneity.

A silk fibroin and perfluorocarbon emulsion enhances surfactant distribution throughout the lungs.

A semifluorinated alkane vehicle stabilizes delta-9-tetrahydrocannabinol and enhances its solubility for topical administration.

Formula I compounds overcome drug resistance in pancreatic cancer by simultaneously inducing apoptosis and inhibiting pro-survival autophagy.

A semifluorinated alkane composition solubilizes obstructive meibum lipids and forms a protective lubricating layer on the ocular surface.

Restoring brain interstitial glial potassium levels via channel activators addresses cell-autonomous glial dysfunction in schizophrenia.

Formula IA and IB compounds inhibit sphingosine kinases via competitive substrate binding, resolving potency and metabolic stability limitations.

ATR-101 urea derivative reduces tumor size and hormone production, addressing severe side effects from mitotane therapy.